anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The incidence of biliary duct injuries remains higher in laparoscopic cholecystectomy (LC) in comparison to open surgery. The Critical View of Safety (CVS) was introduced by Strasberg as a strategy for reducing this catastrophic complication. AIM: The aim of this study was to evaluate how often an adequate CVS is achieved during LC, the determining factors for its success, and the associated surgical outcomes.
METHODS: This is a prospective study. CVS photographs of all patients who underwent LC by the same surgeon between 2020 and 2023 were taken. Success in achieving CVS was analyzed by the surgeon herself and posteriorly by hepatobiliary specialists. Patients were classified into two groups: CVS achieved and CVS not achieved. Finally, multivariable logistic regression was used to examine the association between preoperatory factors and surgical complications.
RESULTS: Three hundred and nine consecutive patients were submitted to LC. There were 73.5% elective CL and 26.5% acute cholecystitis. The age ranged from 14 to 87 years, and 76.8% were female. The median body mass index was 26.7. Previous abdominal surgeries were present in 64%, and 26% were obese. The CVS was achieved in 79.9% of the patients, and there were no surgical complications in this group. The factors associated with nonachievement were acute cholecystitis (p=0.007), male sex (p=0.014), and previous surgeries (p=0.021). Three patients needed a subtotal cholecystectomy due to severe inflammation. There was no statistical correlation between the identification of CVS and surgical complications.
CONCLUSIONS: The CVS is achieved in most patients. Acute cholecystitis, male sex, and previous abdominal operations are associated with difficulties in obtaining CVS.
The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) updates the KDIGO 2012 guideline and has been developed with patient partners, clinicians, and researchers around the world, using robust methodology. This update, based on a substantially broader base of evidence than has previously been available, reflects an exciting time in nephrology. New therapies and strategies have been tested in large and diverse populations that help to inform care; however, this guideline is not intended for people receiving dialysis nor those who have a kidney transplant. The document is sensitive to international considerations, CKD across the lifespan, and discusses special considerations in implementation. The scope includes chapters dedicated to the evaluation and risk assessment of people with CKD, management to delay CKD progression and its complications, medication management and drug stewardship in CKD, and optimal models of CKD care. Treatment approaches and actionable guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence and the strength of recommendations which followed the "Grading of Recommendations Assessment, Development, and Evaluation" (GRADE) approach. The limitations of the evidence are discussed. The guideline also provides practice points, which serve to direct clinical care or activities for which a systematic review was not conducted, and it includes useful infographics and describes an important research agenda for the future. It targets a broad audience of people with CKD and their healthcare, while being mindful of implications for policy and payment.
Thiamine is an essential vitamin meaning humans must consume thiamine from their diet in order to stay healthy. Low thiamine levels can lead to adverse events. Thiamine is absorbed in the intestine by a transporter protein. This is made by the SLC19A3 gene. The SLC19A3 gene provides instructions for making the thiamine transporter protein, which moves thiamine into cells. Certain drugs, like metformin and trimethoprim, have been shown to interrupt function of the SLC19A3 gene.

Metformin is a first-line therapy for patients with Type 2 diabetes and is associated with improvements in diabetic complications. Trimethoprim is an anti-bacterial drug that is often prescribed to treat infections such as urinary tract infections. At different phases of this study, participants will be administered thiamine, thiamine with metformin, and/or thiamine with trimethoprim to determine whether taking a drug and a vitamin together affects the body's ability to absorb, distribute, and eliminate thiamine. The levels of thiamine in the participants' blood and urine will be measured before and after taking thiamine or thiamine in combination with metformin and/or trimethoprim.
PURPOSE:To obtain an cod-liver oil having good taste and vitamin with high unit free from a fishy smell and an unpleasant smell, by using a liver of marine product by a method applying no heat. CONSTITUTION:A liver of marine product such as shark, cod, whale, etc. is ground into a suspension, the suspension is frozen, allowed to stand, and thawed naturally. A solid material, etc. on the surface layer of the formed liquid material are removed, water and impurities separated into the bottom layer part are removed. The prepared liquid material is dehydrated, to give a cod-liver oil containing vitamin with high unit. The cod-liver oil has no destruction of contained components, and can keep its safety without changing the component balance. It can stand longer period preservation than an existing product prepared by heat treatment method. The cod-liver oil is useful as a material for a cosmetic such as hand cream, effective for athlet's food, diseases and disorders of stomach, intestine, lung, and other internal organs, and it is a natural healthy food useful for promoting metabolic functions of body and improving physical strength.
Resistant hypertension is defined as a blood pressure of 140/90 mmHg or higher despite adherence to at least three antihypertensive drugs (including one diuretic), accounting for 20% to 30% of patients with hypertension. Compared with patients with well-controlled blood pressure, the cardiovascular risk of resistant hypertension is increased by about 50%. Limb remote ischemic conditioning (LRIC) triggers endogenous protective effects through transient and repeated ischemia in the limb to protect remote tissues and organs. The mechanisms of LRIC involve the regulation of the autonomic nervous system, the release of humoral factors, improvement of vascular endothelial function, and modulation of immune/inflammatory responses, which can antagonize the pathogenesis of hypertension through multiple pathways to lead to a drop in BP theoretically. This theory has been preliminarily confirmed by several small sample-size studies in non-resistant hypertension. This study aims to explore the efficacy and safety of remote ischemia adaptation for the treatment of resistant hypertension.
Compounds and methods are provided for inhibiting a CREB-CBP protein-protein interaction in a sample. In some cases, the method includes modulating transcription of CREB in a cell that overexpresses CREB. Also provided are methods of inhibiting the proliferation of a cancer cell. The subject CREB transcription inhibitor compounds include a substituted salicylamide or a prodrug thereof. Methods of alleviating symptoms associated with cancer (e.g., Acute Myeloid Leukemia (AML) or Acute Lymphomblastic Leukemia (ALL)) in a subject in need thereof are also provided. Pharmaceutical compositions including the subject compounds find use in treating cancer. The subject compounds may be formulated or provided to a subject in combination with a second agent, e.g. an anticancer agent.
The invention discloses a medical suspended preparation and a preparation method thereof. The medical suspended preparation is used for treating and preventing diseases or regulating physiological functions through medical information without contacting human or animal body skins. The basic structure of the medical suspended preparation is composed of a medicament bank (1), a container (4) and a connecting piece (5). Contents (2) are medicaments having pharmacological activities. When the preparation is used in treatment, no medicinal material matters enter a human or animal body, so safety problem as well as the simulation of oral preparations to the gastrointestinal tract, the first-pass effect of the gastrointestinal tract, the drawbacks of pains, cross-infection risks and injection and infusion reactions of injections, the simulation and damage of transdermal patchs to skin, the damage of adhesive to skin, and the like are avoided. The product can be used repeatedly, so the consumption of medicaments is reduced greatly, medicament resources are saved, environmental pollution caused by pharmaceutical industry is reduced greatly, and ecological is protected. The preparation is simple, convenient and safe to use and is particularly suitable for treating the aged and weak, children, people with mental retardation and animals.
Symptoms associated with discontinuation of other SSRIs or SNRIs have been reported. [See WARNINGS AND PRECAUTIONS (5.9)]. Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.
The invention discloses a kind of compound Anlin Babituo injection and preparation method thereof.It comprises the steps：1. appropriate hot water for injection, natrium adetate are added in dense preparing tank, stirring and dissolving adds aminopyrine, antipyrine and barbital, stirring and dissolving；2. filter is returned to after clear and bright with Suzhou sand stick, filter into dilute preparing tank；3. water for injection is added to full dose, is stirred；4. filtered with Suzhou sand stick, 0.45 μm and 0.22 μm of polyether sulfone fin to clear and bright；5. sampling and testing intermediates content and pH value；If it is every it is qualified after, by medical filtration into receiver；6. the decoction in receiver is filtered through 0.22 μm of polyether sulfone fin, and input reservoir supplies embedding；7. sterilize for 115 DEG C, 30 minutes.Compound Anlin Babituo injection produced by the present invention steady quality during production, storage and use is reliable, can avoid oxidation.The preparation method of the present invention reduces hydrolysis rate and content fall.
1,178,537. Antitussive and analgesic compositions. RECKITT & SONS Ltd. 11 Oct., 1967 [20 Oct., 1966; 2 May, 1967], Nos. 47063/66 and 20322/67. Heading A5B. [Also in Division C2] Antitussive compositions comprise a carrier or diluent and an ester of the formula: wherein R represents a C 5-7  alicyclic group, a C 1-8  alkyl group, a C 3-8  alkenyl or alkynyl group or a C 1-8  alkyl group substituted on one of its carbon atoms by an alicyclic, aryl, aryloxy, morpholino or tertiary amino group, providing that the C atom adjacent to the oxygen of the ester group is not unsaturated and does not bear an amino group or substituted amino group. The ethyl ester is stated to be useful as an analgesic. The compositions may be in conventional forms for oral, parenteral and rectal administration. Antitussive compositions may additionally comprise antiseptics, expectorants and salivation promoters e.g. cetyl pyridinium chloride, NH 4 Cl, guaiaphenesin and citric acid. Analgesic compositions may additionally comprise other analgesics and antiinflammatory compounds, e.g. aspirin and paracetamol and caffeine.
In a placebo-controlled clinical trial of patients with RA, no difference was detected in anti- pneumococcal antibody response between adalimumab and placebo treatment groups when the pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently with adalimumab. Similar proportions of patients developed protective levels of anti-influenza antibodies between adalimumab and placebo treatment groups; however, titers in aggregate to influenza antigens were moderately lower in patients receiving adalimumab. The clinical significance of this is unknown. Patients on YUSIMRY may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving adalimumab products.

It is recommended that pediatric patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating YUSIMRY therapy. Patients on YUSIMRY may receive concurrent vaccinations, except for live vaccines.

The safety of administering live or live-attenuated vaccines in infants exposed to adalimumab products in utero is unknown. Risks and benefits should be considered prior to vaccinating (live or live-attenuated) exposed infants [see Use in Specific Populations (8.1, 8.4)].
BACKGROUND: Prenatal alcohol exposure (PAE) has been linked to congenital heart disease and fetal alcohol syndrome. The heart primarily relies on mitochondria to generate energy, so impaired mitochondrial function due to alcohol exposure can significantly affect cardiac development and function. Our study aimed to investigate the impact of PAE on myocardial and mitochondrial functions in offspring mice.
METHODS: We administered 30% alcohol (3 g/kg) to pregnant C57BL/6 mice during the second trimester. We assessed cardiac function by transthoracic echocardiography, observed myocardial structure and fibrosis through staining tests and electron transmission microscopy, and detected cardiomyocyte apoptosis with dUTP nick end labeling assay and real-time quantitative PCR. Additionally, we measured the reactive oxygen species content, ATP level, and mitochondrial DNA copy number in myocardial mitochondria. Mitochondrial damage was evaluated by assessing the level of mitochondrial membrane potential and the opening degree of mitochondrial permeability transition pores.
RESULTS: Our findings revealed that PAE caused cardiac systolic dysfunction, ventricular enlargement, thinned ventricular wall, cardiac fibrosis in the myocardium, scattered loss of cardiomyocytes, and disordered arrangement of myocardial myotomes in the offspring. Furthermore, we observed a significant increase in mitochondrial reactive oxygen species content, a decrease in mitochondrial membrane potential, ATP level, and mitochondrial DNA copy number, and sustained opening of mitochondrial permeability transition pores in the heart tissues of the offspring.
CONCLUSIONS: These results indicated that PAE had adverse effects on the cardiac structure and function of the newborn mice and could trigger oxidative stress in their myocardia and contribute to mitochondrial dysfunction.
The present invention relates to a hair care treatment composition having excellent damaged hair recovery and hair protection functions and a method for manufacturing the same wherein the hair care treatment composition can be solely used as a hair care treatment solution or can be used as a base material for shampoo, a hair dyeing agent, and a hair care formulation. The hair care treatment composition having excellent damaged hair recovery and hair protection functions of the present invention comprises purified water, as a main ingredient, deep seawater, and a mixture, as a mixture extracted from natural materials, of a bladder wrack algae extract, a giant kelp extract, a seaweed extract, a gulfweed extract, a Pinus sylvestris bark extract, a Japanese cedar extract, a bamboo water extract, a mugwort extract, and a Torreya nucifera extract. The hair care treatment composition having excellent damaged hair recovery and hair protection functions of the present invention has minerals of deep seawater as a hair filling ingredient and a large amount of negative electrons and comprises selected extracts of natural materials at a certain ratio. As the extracts have a large amount of negative electrons, potential difference of +/- between a surface of hair and the inside of the hair is generated when the composition is applied to damaged hair, and then electrons move to be balanced. At this point, a filling material, comprising moisture, minerals, and protein, penetrates the inside of the hair and then effectively recovers the hair damaged as a result of excessive hair procedures. Accordingly, the hair care treatment composition recovers the hair into healthy hair which is thick, strong, and shiny. In addition, materials with negative charge remaining on the surface can effectively protect the hair from a dry external environment.
BACKGROUND: Patients with Multiple System Atrophy (MSA) frequently report non-motor symptoms, and several research groups have highlighted this.
OBJECTIVE: We systematically searched for and reviewed papers assessing prevalence of non-motor symptoms (NMS) in MSA patients as reported in the scientific literature.
METHODS: We performed a systematic review of studies of subjects with MSA (involving > 10 patients) who were assessed for NMS, published in the English literature in PUBMED and EMBASE databases from 1947-2022.
RESULTS: 23 research papers, with data from 2648 clinically diagnosed and 171 pathologically verified cases of MSA were included, along with 238 controls. Mean age for MSA cases was 61.3 (9.2) years, mean disease duration 3.6 (2.7) years. 57.9% were male. Our analysis showed that the prevalence of cognitive issues in MSA varied widely (between 15-100%); dementia per se was uncommon, but assessment in advanced stages of MSA is impacted by unintelligible speech (which may be noted in a quarter of cases). The prevalence of depressive symptoms in MSA was between 44-88%. Sleep disturbances were reported by 17-89%, with REM-sleep behaviour disorder (RBD) rates as high as 75%. Pain was reported by 40-47% of patients: rheumatic or musculoskeletal sources of pain being commonest. Fatigue was reported by 29-60% of patients. Symptoms of autonomic failure in MSA were seen in 34-96.5% patients at baseline.
CONCLUSION: In routine clinical practice, NMS in MSA are under-recognised by clinicians. These impact hugely on patient quality of life and contribute to their overall morbidity. A methodical ascertainment of these complaints will address an unmet need, and lead to a more holistic approach of care for individuals with MSA.
Innate immune memory endows innate immune cells with antigen independent heightened responsiveness to subsequent challenges. The durability of this response can be mediated by inflammation induced epigenetic and metabolic reprogramming in hematopoietic stem and progenitor cells (HSPCs) that are maintained through differentiation to mature immune progeny. Understanding the mechanisms and extent of trained immunity induction by pathogens and vaccines, such as BCG, in HSPC remains a critical area of exploration with important implications for health and disease. Here we review these concepts and present new analysis to highlight how inflammatory reprogramming of HSPC can potently alter immune tone, including to enhance specific anti-tumor responses. New findings in the field pave the way for novel HSPC targeting therapeutic strategies in cancer and other contexts of immune modulation. Future studies are expected to unravel diverse and extensive effects of infections, vaccines, microbiota, and sterile inflammation on hematopoietic progenitor cells and begin to illuminate the broad spectrum of immunologic tuning that can be established through altering HSPC phenotypes. The purpose of this review is to draw attention to emerging and speculative topics in this field where we posit that focused study of HSPC in the framework of trained immunity holds significant promise.
Colorectal cancer (CRC) in pregnancy is sporadic. We reported a case of a woman at 23 + 4 weeks of gestation who presented with abdominal pain. The patient underwent an ultrasound and MRI, during which a colonic mass was noted. Considering a probable incomplete intestinal obstruction, a colonoscopy, biopsy, and colonic stenting were performed by a multidisciplinary team. However, sudden hyperthermia and CT demonstrated intestinal perforation, and an emergency caesarean section and colostomy were conducted. The histological analysis confirmed moderately high-grade adenocarcinoma.
The safety and effectiveness of XHANCE in pediatric patients have not been established.

Effects on Growth

Controlled clinical trials have shown that nasal corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. This effect was observed in the absence of laboratory evidence of HPA axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The long-term effects of this reduction in growth velocity associated with nasal corticosteroids, including the impact on final adult height, are unknown. The potential for “catch-up” growth following discontinuation of treatment with nasal corticosteroids has not been adequately studied. The growth of pediatric patients receiving nasal corticosteroids should be monitored routinely (e.g., via stadiometry). The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained and the risks associated with alternative therapies.

Controlled clinical trials have shown that corticosteroids orally inhaled into the lungs may cause a reduction in growth in pediatric patients. In these trials, the mean reduction in growth velocity was approximately 1 cm/year (range: 0.3 to 1.8 cm/year) and appeared to depend upon dose and duration of exposure. The effects on growth velocity of treatment with corticosteroids orally inhaled into the lungs for over 1 year, including the impact on final adult height, are unknown. The growth of children and adolescents receiving corticosteroids should be monitored routinely (e.g., via stadiometry) [see Warnings and Precautions (5.8)].
INTRODUCTION/BACKGROUND: Though CIDP and ATM are both inflammatory disorders of the nervous system with distinct features, they rarely occur together in the same individual.
CASE PRESENTATION: A 41-year-old male trader was admitted with 10 10-day history of paraplegia and weakness of upper limbs. The illness started with lower limb paresthesia, weakness of the left leg, then the right leg after 5 days, proceeding to paraplegia, weakness of upper arms, urine retention, and constipation 3 days before presentation. There was a brief fever; no sore throat or cough; no travel outside the country; and no vaccination. He smoked 10 cigarette packs yearly and drank alcohol occasionally. He was unmarried. Vital signs were stable with normal mentation; oxygen saturation 98%; no cranial nerve deficits; flaccid paraplegia; flaccid bilateral upper limbs weakness (MRC 1/5) and symmetrical sensory loss to the level of T4. HIV, hepatitis B, and C antibodies were all negative; hematological, renal, and liver functions were normal. CSF cyto-albumin dissociation and hyperintensities of the cervical and upper thoracic spinal cord on MRI necessitated a diagnosis of mixed CIDP and ATM. Although the patient could not buy IV immunoglobulin, he has been on prednisolone; and 40 days later flaccid paraplegia and sensory loss persist, but tone and reflexes have returned to normal, and power is MRC 3/5. He remains conscious, is dyspnoeic, and is currently on a mechanical ventilator with a feeding nasogastric tube and urinary catheter in situ.
CONCLUSION: Both CIDP and ATM are distinct severe neuro-inflammatory diseases requiring emergency and intensive care management as each has potential for high mortality outcomes.